戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tients inevitably develop resistance to this angiogenic inhibitor.
2 whereas thrombospondin-1 (TSP-1) is a potent angiogenic inhibitor.
3 eolytic fragment of plasminogen and a potent angiogenic inhibitor.
4 epithelium-derived factor (PEDF) is a potent angiogenic inhibitor.
5 epithelium-derived factor (PEDF) is a potent angiogenic inhibitor.
6 tion of tumor angiogenesis and evaluation of angiogenic inhibitors.
7  devoid of angiogenesis but containing bound angiogenic inhibitors.
8  their matrix-bound and released circulating angiogenic inhibitors.
9 in the balance of angiogenic stimulators and angiogenic inhibitors.
10 herapeutic approaches for safe and effective angiogenic inhibitors.
11 upport the idea that different regulation of angiogenic inhibitors and stimulators under ischemia are
12 pigment epithelium-derived factor (PEDF), an angiogenic inhibitor, and vascular endothelial growth fa
13 er MMPs are involved in the generation of an angiogenic inhibitor, angiostatin.
14 use of these and other natural and synthetic angiogenic inhibitors as anticancer drugs is currently u
15                               Fumagillin, an angiogenic inhibitor, binds to methionine aminopeptidase
16  age-related decline in the expression of an angiogenic inhibitor contributes to the imbalance of ang
17 AAV) vector expressing angiostatin, a potent angiogenic inhibitor, effectively suppresses human gliom
18                           The effects of the angiogenic inhibitors endostatin, angiostatin, and TNP-4
19  endothelium (ECs and EC precursors) natural angiogenic inhibitors enhance nuclear factor-kappaB (NF-
20 ide a useful model for studying the roles of angiogenic inhibitors in neovascular disorders such as d
21  how to schedule an a priori given amount of angiogenic inhibitors in order to minimize the tumor vol
22 matrix (ECM) and high levels of protease and angiogenic inhibitors including maspin, tissue inhibitor
23 derable sensitivity of this assay to several angiogenic inhibitors, including kinase inhibitors and m
24 tion of plasminogen kringle 5 (K5), a potent angiogenic inhibitor, inhibits ischemia-induced retinal
25                                Sorafenib, an angiogenic inhibitor, is the only drug approved for use
26 n is regulated by constitutive expression of angiogenic inhibitors like thrombospondin-1.
27    Emerging targeted therapies, particularly angiogenic inhibitors, may prove useful in refractory me
28 ct of nanoparticle-mediated gene delivery of angiogenic inhibitors on retinal inflammation, vascular
29 g this model, we investigated the effects of angiogenic inhibitors on sprouting morphogenesis.
30 trophic PEDF-derived peptides, ovalbumin and angiogenic inhibitors, only full-length PEDF competed ef
31 ial growth factor (VEGF) and up-regulates an angiogenic inhibitor, pigment epithelium-derived factor
32 n, markedly decreased protease inhibitor and angiogenic inhibitor production, high levels of protease
33             In addition, tumors may activate angiogenic inhibitors such as angiostatin and endostatin
34                       Soluble Flt (sFlt), an angiogenic inhibitor that binds VEGF-A, significantly de
35 ospondins 1 and 2 are members of a family of angiogenic inhibitors that are regulated by several onco
36  quiescent, in part because of the action of angiogenic inhibitors that prevent vessels from invading
37 2, IL-6, etc.) and downregulation of several angiogenic inhibitors (THBS1, CXCL14, and CXCL10).
38 hether prenatal treatment with either of two angiogenic inhibitors, the COX-2 inhibitor celecoxib, or
39 scertain the participation of the endogenous angiogenic inhibitor thrombospondin-1 (TSP1) in tumor pr
40 ABT-510, a peptide derivative of the natural angiogenic inhibitor thrombospondin-1.
41 sac cells, including angiopoietin-2, and the angiogenic inhibitors thrombospondin-1 and angiopoietin-
42  stimulators and up-regulation of endogenous angiogenic inhibitors, thus leading toward restoration o
43 mid of plasminogen kringle 5 (K5), a natural angiogenic inhibitor, was encapsulated with poly(lactide
44 constitutively express high levels of active angiogenic inhibitors which include TIMP-1, thrombospond

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。